# **Mille Lacs Health System**

200 North Elm Street Onamia, MN 56359 www.millelacshealth.com



# **Clinical Quality Measures**

2023 measurement year

Measure		Rating	Rate	
Adolescent Depression	PHQ-9 Utilization*	-	-	
	Follow-up at Six Months	-	-	
	Response at Six Months	-	-	
	Remission at Six Months	-	-	
scer	Follow-up at 12 Months	-	-	
ole	Response at 12 Months	-	-	
Ad	Remission at 12 Months	-	-	
	PHQ-9 Utilization*	Below	37.30%	
on	Follow-up at Six Months	-	-	
essi	Response at Six Months	-	-	
epr	Remission at Six Months	-	-	
Adult Depression	Follow-up at 12 Months	-	-	
	Response at 12 Months	-	-	
	Remission at 12 Months	-	-	
Adolescent Mental Health and/or Depression Screening*		Below	86.10%	
Colorectal Cancer Screening		Below Expected	40.10%	
Optimal Asthma Control - Adults		Below Expected	16.00%	
Optin	nal Asthma Control - Children	Below Expected	14.10%	
Optimal Diabetes Care  HbA1c Control  BP Control  Daily Aspirin Use  Statin Use  Tobacco-Free		Below Expected Below Expected Below Expected Expected Expected Below Expected	<b>22.50%</b> 56.80% 64.70% 97.70% 81.90% 74.00%	
Optimal Vascular Care BP Control Daily Aspirin Use Statin Use Tobacco-Free		Below Expected  Below Expected  Expected  Expected  Expected	<b>39.20%</b> 66.00% 81.50% 93.10% 72.00%	

<sup>-</sup> Medical group not assigned to measure, did not have results, or did not meet reporting threshold

<sup>\*</sup>Measure not risk adjusted

# Mille Lacs Health System

### Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	Below	45.90%
Breast Cancer Screening	Below	54.20%
Cervical Cancer Screening	Below	51.90%
Childhood Immunization Status (Combo 10)	-	-
Chlamydia Screening in Women	Below	38.50%
Controlling High Blood Pressure	Below	48.50%
Diabetes Eye Exam	Below	44.70%
Immunizations for Adolescents (Combo 2)	-	-
Follow-up Care for Children Prescribed ADHD Medication	-	-
Osteoporosis Management in Women Who Had a Fracture	-	-
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	-	-

<sup>-</sup> Medical group not assigned to measure, did not have results, or did not meet reporting threshold

#### **Ratings**

*Above*: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

**Below:** Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

#### **Total Cost of Care**

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	\$927	Higher than average	30.90%
Adults	\$1,082	Higher than average	30.30%
Pediatric	-	-	-